Pasar al contenido principal

ABORDAJE DE LAS ENFERMEDADES CRONICAS CON NUEVOS ENFOQUES TERAPEUTICOS PARA MODULAR EL SISTEMA ENDOCANNABINOIDE

RTI2018-095544-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Neuroprotective Effect of IND1316, an Indole-Based AMPK Activator, in Animal Models of Huntington Disease

  • Vela, Marta
  • Sanchis, Ana
  • Bono-Yagüe, José
  • Cumella, José
  • Lagartera, Laura
  • Pérez, Concepción
  • Priego, Eva María
  • Campos, Angela
  • Sanz, Pascual
  • Vázquez-Manrique, Rafael P.
  • Castro, Ana
  • García-Gimeno, María Adelaida|||0000-0002-6483-3912
[EN] Aggregation of mutant huntingtin, because of an expanded polyglutamine track, underlies the cause of neurodegeneration in Huntington disease (HD). However, it remains unclear how some alterations at the cellular level lead to specific structural changes in HD brains. In this context, the neuroprotective effect of the activation of AMP-activated protein kinase (AMPK) appears to be a determinant factor in several neurodegenerative diseases, including HD. In the present work, we describe a series of indole-derived compounds able to activate AMPK at the cellular level. By using animal models of HD (both worms and mice), we demonstrate the in vivo efficacy of one of these compounds (IND1316), confirming that it can reduce the neuropathological symptoms of this disease. Taken together, in vivo results and in silico studies of druggability, allow us to suggest that IND1316 could be considered as a promising new lead compound for the treatment of HD and other central nervous system diseases in which the activation of AMPK results in neuroprotection., We thank the CGC, which is funded by the NIH Office of Research Infrastructure Programs (P40 OD010440), for providing worm strains. RPVM is a Miguel Servet type II researcher (CPII16/00004) funded by Instituto de Salud Carlos III (ISCIII, Madrid, Spain). Grants from the ISCIII (PI17/00011 and PI20/00114), the Spanish Ministerio de Ciencia Innovacion y Universidades (RTI2018-095544-B-I00) and the Fundacio Marato de TV3 (Ref.: 559) were used to perform this work . All grants from ISCIII are co-financed by the European Development Regional Fund "A way to achieve Europe" (ERDF). Funds from the Fundacion Ramon Areces were also used (CIVP19S8119). J.B.Y . holds a grant by the Generalitat Valenciana and the European Social Fund (ACIF/2019/249). R.V.M. received an Ayuda Miguel Gil grant to RPVM (VII Convocatoria Ayudas a la Investigacion MHER, 2019, cofinanced by Colegio Oficial de Farmaceuticos de Sevilla and Fundacion Cajasol). R.V.M. has also received funds from the Asociacion Valenciana de Enfermedad de Huntington (AVAEH) . This work was also supported by an intramural ACCI2016 grant from the CIBERER-ISCiii to A.C., P.S., and R.V.M.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Antimalarial quinoline drugs inhibit β-hematin and increase free hemin catalyzing peroxidative reactions and inhibition of cysteine proteases

  • Herraiz Tomico, Tomás
  • Guillén Fuerte, Hugo
  • González Peña, Diana
  • Arán, Vicente J.
Malaria caused by Plasmodium affects millions people worldwide. Plasmodium consumes hemoglobin during its intraerythrocytic stage leaving toxic heme. Parasite detoxifies free heme through formation of hemozoin (β-hematin) pigment. Proteolysis of hemoglobin and formation of hemozoin are two main targets for antimalarial drugs. Quinoline antimarial drugs and analogs (β-carbolines or nitroindazoles) were studied as inhibitors of β-hematin formation. The most potent inhibitors were quinacrine, chloroquine, and amodiaquine followed by quinidine, mefloquine and quinine whereas 8-hydroxyquinoline and β-carbolines had no effect. Compounds that inhibited β-hematin increased free hemin that promoted peroxidative reactions as determined with TMB and ABTS substrates. Hemin-catalyzed peroxidative reactions were potentiated in presence of proteins (i.e. globin or BSA) while antioxidants and peroxidase inhibitors decreased peroxidation. Free hemin increased by chloroquine action promoted oxidative reactions resulting in inhibition of proteolysis by three cysteine proteases: papain, ficin and cathepsin B. Glutathione reversed inhibition of proteolysis. These results show that active quinolines inhibit hemozoin and increase free hemin which in presence of HO that abounds in parasite digestive vacuole catalyzes peroxidative reactions and inhibition of cysteine proteases. This work suggests a link between the action of quinoline drugs with biochemical processes of peroxidation and inhibition of proteolysis., The authors thank Spanish Government-FEDER through projects RTI2018-093940-B-I00, RTI2018-095544-B-I00 and SAF-2015-66690-R. EY and FV are recipients of “Garantía Juvenil” fellowships from Comunidad de Madrid (Fondo Social Europeo-Iniciativa de Empleo Juvenil).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System

  • Lago-Fernández, Ana
  • Zarzo-Arias, Sara
  • Jagerovic, Nadine
  • Morales, Paula
© 2021 by the authors., Cannabinoids have shown to exert their therapeutic actions through a variety of targets. These include not only the canonical cannabinoid receptors CB1R and CB2R but also related orphan G protein-coupled receptors (GPCRs), ligand-gated ion channels, transient receptor potential (TRP) channels, metabolic enzymes, and nuclear receptors. In this review, we aim to summarize reported compounds exhibiting their therapeutic effects upon the modulation of CB1R and/or CB2R and the nuclear peroxisome proliferator-activated receptors (PPARs). Concomitant actions at CBRs and PPARα or PPARγ subtypes have shown to mediate antiobesity, analgesic, antitumoral, or neuroprotective properties of a variety of phytogenic, endogenous, and synthetic cannabinoids. The relevance of this multitargeting mechanism of action has been analyzed in the context of diverse pathologies. Synergistic effects triggered by combinatorial treatment with ligands that modulate the aforementioned targets have also been considered. This literature overview provides structural and pharmacological insights for the further development of dual cannabinoids for specific disorders., This research was funded by the Spanish Ministry of Science and Innovation, grant number MICIU/FEDER: RTI2018-095544-B-I00 and the Spanish National Research Council (CSIC), grant number PIE-201580E033. PM acknowledges the Comunidad de Madrid ‘Atracción de Talento’ program, fellowship number 2018-T2/BMD-10819., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Therapeutic Exploitation of GPR18: Beyond the Cannabinoids?

  • Morales, Paula
  • Lago-Fernández, Ana
  • Hurst, D. P.
  • Sotudeh, N.
  • Brailoiu, E.
  • Reggio, P. H.
  • Abood, Mary E.
  • Jagerovic, Nadine
GPR18 is a G-protein-coupled receptor that belongs to the orphan class A family. Even though it shares low sequence homology with the cannabinoid receptors CBR and CBR, a growing body of research suggests its relationship with the endocannabinoid system, not only because it is able to recognize cannabinoid ligands but also because of its expression and ability to heteromerize with CBRs. In this review, we aim to analyze the biological relevance, reported modulators, and structural features of GPR18. In order to guide future drug design in this field, highlights from molecular modeling of GPR18 will be provided., P.M., A.L.-F., and N.J. are supported by the Ministry of Science, Innovation, and Universities, Spain (MCIU)/FEDER Grant RTI2018-095544-B-I00, and the Spanish National Research Council (CSIC) Grant PIE-201580E033. M.E.A., P.H.R., and N.J. are supported by National Institutes of Health Grant R01 DA0455698-01. P.M. acknowledges the Comunidad de Madrid (CM) program “Atraccion de Talento” Grant 2018-T2/BMD10819.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Discovery of Homobivalent Bitopic Ligands of the Cannabinoid CB2 Receptor

  • Morales, Paula
  • Navarro, Gemma
  • Gómez-Autet, Marc
  • Redondo, Laura
  • Fernández-Ruiz, Javier
  • Pérez-Benito, Laura
  • Cordomí, Arnau
  • Pardo, Leonardo
  • Franco, Rafael
  • Jagerovic, Nadine
Single chemical entities with potential to simultaneously interact with two binding sites are emerging strategies in medicinal chemistry. We have designed, synthesized and functionally characterized the first bitopic ligands for the CB2 receptor. These compounds selectively target CB2 versus CB1 receptors. Their binding mode was studied by molecular dynamic simulations and site¿directed mutagenesis., This work was supported by the MICIU/FEDER (RTI2018- 095544-B-I00, PID2019-109240RB-I00, SAF2017-84117-R), and by the CSIC (PIE-201580E033). P.M. is grateful to the CM program “Atraccijn de Talento Investigador” number 2018-T2/ BMD-1081.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Occurrence, formation from D‑fructose and 3‑deoxyglucosone, and activity of the carbohydrate-derived β‑carbolines in foods

  • Herraiz Tomico, Tomás
  • Vera, Fernando
β-Carbolines are naturally occurring bioactive alkaloids. In this work, carbohydrate-derived β-carbolines (βCs), 1-(1,3,4,5-tetrahydroxypent-1-yl)-β-carboline isomers (1a/b), 1-(1,4,5-trihydroxypent-1-yl)-β-carboline (2), 1-(1,5-dihydroxypent-3-en-1-yl)-β-carboline (3), and 1-(1,2,3,4,5-pentahydroxypent-1-yl)-β-carboline (4) were identified and analyzed in commercial foods. The concentrations of βCs 1–4 in foods ranged from undetectable to 11.4 μg/g levels, suggesting their intake in the diet. Processed foods contained higher amounts than fresh or unprocessed foods, and the highest content was found in processed tomato and fruit products, sauces, and baked foods. βCs 1–3 were formed in foods during heating, and 1a/b were the main compounds. The formation of carbohydrate-derived βCs was studied in model reactions of tryptophan and carbohydrates. They formed in reactions of tryptophan with glucose under acidic conditions at temperatures higher than 80 °C. The formation of 1a/b was favored, but 2–3 increased at high temperatures. Noticeably, the βCs 1–3 formed in the reactions of tryptophan with fructose or sucrose, and the formation from fructose was much higher than from glucose. Thus, fructose was the main carbohydrate involved in the formation of 1–3, whereas sucrose gave these βCs after acid hydrolysis. It is shown for the first time that the mechanism of formation of βCs 1–3 occurs from the sugar intermediate 3-deoxyglucosone that reacts with tryptophan affording these carbohydrate-derived βCs. A mechanism of reaction to give βCs 1–3 is proposed that relies on the tautomerism (keto–enediol or enamine–imine) of intermediates involved in the reaction. Carbohydrate βCs 1–4 were assessed as inhibitors of monoamine oxidase (MAO), as antioxidants, and for their interaction with DNA. They were not good inhibitors of MAO-A or -B, were poor antioxidants, and did not appreciably interact with DNA., The authors thank Spanish Government-Feder (projects RTI2018-093940-B-I00 and RTI2018-095544-B-I00) and project 200470E658 (CSIC). F.V. thanks Comunidad de Madrid (CAM) and Fondo Social Europeo (EU)-Iniciativa de Empleo Juvenil for a Garantia Juvenil contract. The authors thank Dr. Vicente Arán for his help in the discussion, and Haroll Mateo Felix for his technical assistance. H.M.F. is a recipient of a Garantia Juvenil contract from Comunidad de Madrid (Fondo Social Europeo-Iniciativa de Empleo Juvenil)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel indolic AMPK modulators induce vasodilatation through activation of the AMPK–eNOS–NO pathway

  • Sanz‑Gómez, Marta
  • Aledavood, Elnaz
  • Beroiz‑Salaverri, Marina
  • Lagartera, Laura
  • Vega‑Martín, Elena
  • Gil‑Ortega, Marta
  • Cumella, Jose
  • Pérez, Concepción
  • Luque, F. Javier
  • Estarellas, Carolina
  • Fernández-Alfonso, María Soledad
  • Castro Morera, Ana
Endothelial adenosine monophosphate-activated protein kinase (AMPK) plays a critical role in the regulation of vascular tone through stimulating nitric oxide (NO) release in endothelial cells. Since obesity leads to endothelial dysfunction and AMPK dysregulation, AMPK activation might be an important strategy to restore vascular function in cardiometabolic alterations. Here, we report the identification of a novel AMPK modulator, the indolic derivative IND6, which shows affinity for AMPKα1β1γ1, the primary AMPK isoform in human EA.Hy926 endothelial cells. IND6 shows inhibitory action of the enzymatic activity in vitro, but increases the levels of p-Thr174AMPK, p-Ser1177eNOS and p-Ser79ACC in EA.Hy926. This paradoxical finding might be explained by the ability of IND6 to act as a mixed-type inhibitor, but also to promote the enzyme activation by adopting two distinct binding modes at the ADaM site. Moreover, functional assays reveal that IND6 increased the eNOS-dependent production of NO and elicited a concentration-dependent vasodilation of endothelium-intact rat aorta due to AMPK and eNOS activation, demonstrating a functional activation of the AMPK–eNOS–NO endothelial pathway. This kinase inhibition profile, combined with the paradoxical AMPK activation in cells and arteries, suggests that these new chemical entities may constitute a valuable starting point for the development of new AMPK modulators with therapeutic potential for the treatment of vascular complications associated with obesity., his research was funded by Fundación Eugenio Rodríguez Pascual, the Spanish Ministerio de Economía y Competitividad (MDM-2017-0767), the Spanish Ministerio de Ciencia Innovación y Universidades (RTI2018- 095544-B-I00) and the Generalitat de Catalunya (2017SGR1746) for financial support. Computational resources from the Barcelona Supercomputing Center (BSC; BCV-2019-1-0009 and BCV-2019-2-0017) and the Consorci de Serveis Universitaris de Catalunya (CSUC; Molecular Recognition project) are acknowledged. E.A. thanks AGAUR (Generalitat of Catalunya; 2019FI_B2_00001) for her fellowship. M.S.G. thanks Universidad Com- plutense de Madrid for her fellowship., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Formation, characterization, and occurrence of β-carboline alkaloids derived from α-dicarbonyl compounds and l -tryptophan

  • Herraiz Tomico, Tomás
  • Peña, Adriana
  • Mateo, Haroll
  • Herraiz Carasa, Marta
  • Salgado, Antonio
β-Carbolines (βCs) are naturally occurring bioactive alkaloids, whereas α-dicarbonyl compounds are reactive substances generated in foods and in vivo. In this work, l-tryptophan reacted with α-dicarbonyl compounds affording new β-carbolines. Glyoxal afforded 1-hydroxymethyl-β-carboline (HME-βC) and its 3-carboxylic acid, and methylglyoxal afforded 1-(1-hydroxyethyl)-β-carboline (HET-βC) and its 3-carboxylic acid. 3-Deoxyglucosone afforded 1-(1,3,4,5-tetrahydroxypent-1-yl)-β-carboline isomers (1a/b), 1-(1,4,5-trihydroxypent-1-yl)-β-carboline (2), and 1-(1,5-dihydroxypent-3-en-1-yl)-β-carboline (3). The formation of these βCs increased under acidic conditions and with increasing temperature. A mechanism is proposed explaining the conversion of a carbonyl into a hydroxy group based on tautomerism and cyclization to the dihydro-βC-3-COOH intermediates, which were isolated and gave the βCs. These α-dicarbonyl-derived βCs occurred in model reactions of l-tryptophan with fructose or glucose incubated under heating and can be considered as advanced glycation end products (AGEs). They were also present in foods and formed during heating processes. HET-βC appeared in processed foods, reaching up to 309 ng/g, with the highest amount found in dried tomato, fried onion, toasted bread, and Manuka honey. HME-βC was only detected in some foods with lower amounts than HET-βC. HET-βC appeared in foods as a racemic mixture of enantiomers suggesting the same mechanism of formation as the synthetized product. α-Dicarbonyl-derived βCs (HET-βC, HME-βC, and 1a/b-3) occur in foods and food processing and, therefore, they are ingested during diet., The authors thank the Spanish Government-Feder (projects RTI2018-093940-B-I00 and RTI2018-095544-B-I00) and CSIC for financial support. H.M. and A.P. thank Consejería de Ciencia, Universidades e Innovación de la Comunidad de Madrid (CM) and the “Fondo Social Europeo-Iniciativa de Empleo Juvenil (YEI)” for Garantia Juvenil contracts., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

β-carboline alkaloids in soy sauce and inhibition of monoamine oxidase (MAO)

  • Herraiz Tomico, Tomás
Monoamine oxidase (MAO) oxidizes neurotransmitters and xenobiotic amines, including vasopressor and neurotoxic amines such as the MPTP neurotoxin. Its inhibitors are useful as antidepressants and neuroprotectants. This work shows that diluted soy sauce (1/3) and soy sauce extracts inhibited human MAO-A and -B isozymes in vitro, which were measured with a chromatographic assay to avoid interferences, and it suggests the presence of MAO inhibitors. Chromatographic and spectrometric studies showed the occurrence of the β-carboline alkaloids harman and norharman in soy sauce extracts inhibiting MAO-A. Harman was isolated from soy sauce, and it was a potent and competitive inhibitor of MAO-A (0.4 µM, 44 % inhibition). The concentrations of harman and norharman were determined in commercial soy sauces, reaching 243 and 52 μg/L, respectively. Subsequently, the alkaloids 1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid (THCA) and 1-methyl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid (MTCA) were identified and analyzed in soy sauces reaching concentrations of 69 and 448 mg/L, respectively. The results show that MTCA was a precursor of harman under oxidative and heating conditions, and soy sauces increased the amount of harman under those conditions. This work shows that soy sauce contains bioactive β-carbolines and constitutes a dietary source of MAO-A and -B inhibitors., The author thanks CSIC (project 200470E658), and RTI2018-093940-B-100, RTI2018-095544-B-100 and PID2021-1278330B-100 funded by MCIN/AEI /10.13039/501100011033 and ERDF A way of making Europe., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Thienopyrimidine Derivatives as GPR55 Receptor Antagonists: Insight into Structure-Activity Relationship

  • Figuerola-Asencio, Laura
  • Morales, Paula
  • Zhao, Pingwei
  • Hurst, D. P.
  • Sayed, Sommayah S.
  • Colón, Katsuya L.
  • Gómez-Cañas, María
  • Fernández-Ruiz, Javier
  • Croatt, Mitchell P.
  • Reggio, Patricia H.
  • Abood, Mary E.
  • Jagerovic, Nadine
GPR55 is an orphan G-protein coupled receptor involved in various pathophysiological conditions. However, there are only a few noncannabinoid GPR55 ligands reported so far. The lack of potent and selective GPR55 ligands precludes a deep exploration of this receptor. The studies presented here focused on a thienopyrimidine scaffold based on the GPR55 antagonist ML192, previously discovered by high-throughput screening. The GPR55 activities of the new synthesized compounds were assessed using β-arrestin recruitment assays in Chinese hamster ovary cells overexpressing human GPR55. Some derivatives were identified as GPR55 antagonists with functional efficacy and selectivity versus CB1 and CB2 cannabinoid receptors., M.E.A., P.H.R., and N.J. are supported by National Institutes of Health grant R01 DA0455698. M.E.A. and P.Z. thank the financial support NIH P30 DA013429. P.M. and N.J. are supported by the Ministry of Science, Innovation, and Universities, Spain (MCIU)/FEDER grant RTI2018-095544-B-I00 and the Spanish National Research Council (CSIC) grant PIE-201580E033. P.M. acknowledges the Comunidad de Madrid (CM) programme “Atraccion de Talento” number 2018-T2/BMD-10819 and “Juan de la Cierva Incorporación Programme-MICIU” (IJC 2019-042182-I), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting CB2 and TRPV1: Computational Approaches for the Identification of Dual Modulators

  • Morales, Paula
  • Muller, Chanté
  • Jagerovic, Nadine
  • Reggio, Patricia H.
Both metabotropic (CBRs) and ionotropic cannabinoid receptors (ICRs) have implications in a range of neurological disorders. The metabotropic canonical CBRs CB1 and CB2 are highly implicated in these pathological events. However, selective targeting at CB2 versus CB1 offers optimized pharmacology due to the absence of psychoactive outcomes. The ICR transient receptor potential vanilloid type 1 (TRPV1) has also been reported to play a role in CNS disorders. Thus, activation of both targets, CB2 and TRPV1, offers a promising polypharmacological strategy for the treatment of neurological events including analgesia and neuroprotection. This brief research report aims to identify chemotypes with a potential dual CB2/TRPV1 profile. For this purpose, we have rationalized key structural features for activation and performed virtual screening at both targets using curated chemical libraries., This research was funded by the Spanish Ministry of Science and Innovation, grant number MICIU/FEDER: RTI 2018-095544-B-I00 and the Spanish National Research Council (CSIC), grant number PIE-201580E033, and the National Institute on Drug Abuse grant R01 DA003934 (PR) and F31 DA53022 (CM)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Binding Mode to Orthosteric Sites and/or Exosites Underlies the Therapeutic Potential of Drugs Targeting Cannabinoid CB2 Receptors

  • Franco, Rafael
  • Morales, Paula
  • Navarro, Gemma
  • Jagerovic, Nadine
  • Reyes-Resina, Irene
The classical terms agonists and antagonists for G protein coupled receptors (GPCRs) have often become misleading. Even the biased agonism concept does not describe all the possibilities already demonstrated for GPCRs. The cannabinoid CB receptor (CBR) emerged as a promising target for a variety of diseases. Reasons for such huge potential are centered around the way drugs sit in the orthosteric and/or exosites of the receptor. On the one hand, a given drug in a specific CBR conformation leads to a signaling cascade that differs qualitatively and/or quantitatively from that triggered by another drug. On the other hand, a given drug may lead to different signaling outputs in two different tissues (or cell contexts) in which the conformation of the receptor is affected by allosteric effects derived from interactions with other proteins or with membrane lipids. This highlights the pharmacological complexity of this receptor and the need to further unravel the binding mode of CBR ligands in order to fine-tune signaling effects and therapeutic propositions., This work was partially supported by AARFD-17-503612 grant of the US Alzheimer’s Association and by grants SAF 2017-84117-R, RTI 2018-094204-B-I00, RTI 2018-095544-B-I00 and PID 2020-113430RB-I00 funded by Spanish MCIN/AEI/10.13039/501100011033 and, as appropriate, by “ERDF A way of making Europe”, by the “European Union” or by the “European Union Next Generation EU/PRTR”. PM is a postdoctoral fellow supported by the Juan de la Cierva Programme-MICIU (IJC 2019-042182-I). The research group of the University of Barcelona is considered of excellence (grup consolidat #2017 SGR 1497) by the Regional Catalonian Government, which does not provide any specific funding for reagents or for payment of services or Open Access fees, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Assay of MAO inhibition by chromatographic techniques (HPLC/HPLC-MS)

  • Herraiz Tomico, Tomás
Monoamine oxidase (MAO) enzymes (MAO A and B) catalyze the oxidative deamination of biogenic amines, neurotransmitters, and xenobiotic amines and contribute to the regulation of the content of these active substances in mammalian organisms. The oxidation of biogenic amines by MAO produces hydrogen peroxide (H2O2) and aldehydes that represent risk factors for oxidative injury. The inhibitors of MAO are useful as antidepressants and neuroprotective agents. Usually, the assays of MAO determine amine deamination products or measure the H2O2 released by using direct spectrophotometric or fluorimetric methods. Direct methods are more prone to interferences and can afford inaccurate results. Those limitations can be avoided by using chromatographic techniques. This work describes a chromatographic method to assay MAO A and MAO B activity by using kynuramine as a nonselective substrate and the subsequent analysis of 4-hydroxyquinoline by RP-HPLC-DAD-fluorescence and mass spectrometry (MS). Alternatively, the assay uses the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin as a substrate of MAO that is oxidized (bioactivated) to neurotoxic pyridinium cations which are analyzed by HPLC. These methods are applied to assess the inhibition of MAO by bioactive β-carboline alkaloids occurring in foods, plants, and biological systems., The author thank the Spanish Government-FEDER through projects RTI2018-093940-B-I00 and RTI2018-095544-B-I00., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Discovery of Homobivalent Bitopic Ligands of the Cannabinoid CB Receptor

  • Morales, Paula|||0000-0002-6209-8600
  • Navarro Brugal, Gemma|||0000-0003-4654-0873
  • Gómez-Autet, Marc|||0000-0002-6133-988X
  • Redondo, Laura
  • Fernández-Ruiz, Javier|||0000-0002-4490-0604
  • Pérez-Benito, Laura|||0000-0001-9607-9048
  • Cordomí Montoya, Arnau|||0000-0002-3848-2928
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
  • Franco, Rafael|||0000-0003-2549-4919
  • Jagerovic, Nadine|||0000-0003-2642-6969
Single chemical entities with potential to simultaneously interact with two binding sites are emerging strategies in medicinal chemistry. We have designed, synthesized and functionally characterized the first bitopic ligands for the CB receptor. These compounds selectively target CB versus CB receptors. Their binding mode was studied by molecular dynamic simulations and site-directed mutagenesis. Single chemical entities with potential to simultaneously interact with two binding sites are emerging strategies in GPCR pharmacology. We present herein the design, synthesis and functional characterization of the first bitopic ligands for the CB receptor. Molecular understanding of the binding mode was guided by molecular dynamic simulations and site-directed mutagenesis.